Premenstrual dysphoric disorder
|Premenstrual dysphoric disorder|
Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of premenstrual syndrome affecting 3–8% of menstruating women. The disorder consists of a "cluster of affective, behavioral and somatic symptoms" that recur monthly during the luteal phase of the menstrual cycle. PMDD was added to the list of depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders in 2013. The exact pathogenesis of the disorder is still unclear and is an active research topic. Treatment of PMDD relies largely on antidepressants that modulate serotonin levels in the brain via serotonin reuptake inhibitors as well as ovulation suppression using contraception.
Signs and symptoms
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). Like PMS, premenstrual dysphoric disorder follows a predictable, cyclic pattern. Symptoms begin in the late luteal phase of the menstrual cycle (after ovulation) and end shortly after menstruation begins. On average, the symptoms last six days but can start up to two weeks before menses. The most intense symptoms occur two days before the start of menstrual blood flow through the first day of menstrual blood flow. The symptoms should cease shortly after the start of the menstrual period.
The symptoms in PMDD can be both physical and emotional with mood symptom being dominant. The most debilitating symptoms are emotional and include "irritability, depression, mood lability, anxiety, feelings of ‘loss of control’, difficulty concentrating and fatigue." The physical symptoms include "abdominal bloating, breast tenderness, headache and generalized aches."
The etiology of PMDD is still an active area of research. While the timing of symptoms suggests hormonal fluctuations as the cause of PMDD, a demonstrable hormonal imbalance in women with PMDD has not been identified. In fact, levels of reproductive hormones in women with and without PMDD are indistinguishable. It is instead hypothesized that women with PMDD are more sensitive to normal levels of hormone fluctuations, predominantly estrogen and progesterone which produces biochemical events in the nervous system that cause the premenstrual symptoms. These symptoms are more predominant in people who have a predisposition to the disorder.
While the etiology of the PMDs is still under investigation, it is apparent that these disorders are biologically driven and are not simply psychological or cultural phenomena. PMDD is found in women worldwide, indicating a biological basis. Most psychologists infer that this disorder is caused by both reaction to hormone influx and genetic components. There is evidence of heritability of premenstrual symptoms not accounted for by family environment suggesting a genetic component to PMDD; however, which genes are involved is a broader question that is still being investigated. Environmental stress can also be a large contributor to triggering PMDD. While there is likely a genetic component to PMDs, the environment must also be considered. Genetics do not operate in a vacuum, and environmental effects such as stress, hormonal fluctuation, and epigenetics likely play a role as well. History of traumatic stress has been associated with PMDD.
Authoritative diagnostic criteria for PMDD are provided by a number of expert medical guides, notably the DSM-5 which established seven criteria (A through G) for the diagnosis of PMDD.
Criterion A is that in most menstrual cycles during the past year, at least 5 of the following 11 symptoms (including at least 1 of the first 4 listed) must be present in the final week before the onset of menses, start to improve within a few days after the onset of menses, and become minimal or absent in the week postmenses.
- Marked lability (e.g., mood swings)
- Marked irritability or anger
- Markedly depressed mood
- Marked anxiety and tension
- Decreased interest in usual activities
- Difficulty in concentration
- Lethargy and marked lack of energy
- Marked change in appetite (e.g., overeating or specific food cravings)
- Hypersomnia or insomnia
- Feeling overwhelmed or out of control
- Physical symptoms (e.g., breast tenderness or swelling, joint or muscle pain, a sensation of ‘bloating’ and weight gain)
- Marked affective lability (e.g., mood swings; feeling suddenly sad or tearful, or increased sensitivity to rejection).
- Marked irritability or anger or increased interpersonal conflicts.
- Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts.
- Marked anxiety, tension, and/or feelings of being keyed up or on edge.
- Decreased interest in usual activities (e.g., work, school, friends, hobbies).
- Subjective difficulty in concentration.
- Lethargy, easy fatigability, or marked lack of energy.
- Marked change in appetite; overeating; or specific food cravings.
- Hypersomnia or insomnia.
- A sense of being overwhelmed or out of control.
- Physical symptoms such as breast tenderness or swelling, joint or muscle pain, a sensation of "bloating," or weight gain.
Note: The symptoms in Criteria A-C must have been met for most menstrual cycles that occurred in the preceding year.
Criterion D The symptoms are associated with clinically significant distress or interference with work, school, usual social activities, or relationships with others (e.g., avoidance of social activities; decreased productivity and efficiency at work, school, or home).[page needed]
Criterion E The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, persistent depressive disorder (dysthymia), or a personality disorder (although it may co-occur with any of these disorders).[page needed]
Criterion F Criterion A should be confirmed by prospective daily ratings during at least two symptomatic cycles. (Note: The diagnosis may be made provisionally prior to this confirmation.)[page needed]
Criterion G The symptoms are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication, other treatment) or another medical condition (e.g., hyperthyroidism).[page needed]
According to the DSM-5, a diagnosis of PMDD requires the presence of at least five of these symptoms with one of the symptoms being number 1-4 (marked lability, irritability, depressed mood, anxiety and tension). These symptoms should occur during the week before menses and remit after initiation of menses. In order to meet criteria for the diagnosis, the symptoms should be charted prospectively for two consecutive ovulation cycles in order to confirm temporal and cyclical nature of symptoms. The symptoms should also be severe enough to affect normal work, school, or social activities or relationships with others.[page needed]
Other organizations that have published diagnostic criteria for PMDD include the American College of Obstetricians and Gynecologists, the Royal College of Obstetricians and Gynecologists, and the International Society for the Study of Premenstrual Disorders (ISPMD). The ISPMD was a consensus group established by an international multidisciplinary group of experts. The group's diagnostic criteria for PMDD focuses on the cyclic nature of the symptom occurring during the luteal phase of the menstrual cycle, symptoms being absent after menstruation and before ovulation and causing significant impairment. The ISPMD diagnostic criteria for PMDD do not specify symptom characteristics or number of symptoms.
GA34.41 Premenstrual dysphoric disorder
During a majority of menstrual cycles within the past year, a pattern of mood symptoms (depressed mood, irritability), somatic symptoms (lethargy, joint pain, overeating), or cognitive symptoms (concentration difficulties, forgetfulness) that begin several days before the onset of menses, start to improve within a few days after the onset of menses, and then become minimal or absent within approximately 1 week following the onset of menses. The temporal relationship of the symptoms and luteal and menstrual phases of the cycle may be confirmed by a prospective symptom diary. The symptoms are severe enough to cause significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning and do not represent the exacerbation of a mental disorder.
Thus today many well-recognized health organizations in many parts of the world provide guides for the diagnosis of PMDD. As a historical footnote, early drafts of the ICD failed to recognize PMDD as a separate condition. In 2003, before the current ICD 10 guidelines, the Committee for Proprietary Medicinal Products required the manufacturer of Prozac (fluoxetine) to remove PMDD from the list of indications for fluoxetine sold in Europe. Reflecting an earlier approach by the ICD, the committee found in 2003 that PMDD was not a well-established disease entity across Europe, and noted "considerable concern that [people] with less severe pre-menstrual symptoms might erroneously receive a diagnosis of PMDD resulting in widespread inappropriate short and long-term use of fluoxetine."
Medication may be used for women with severe and debilitating symptoms. Selective serotonin reuptake inhibitors (SSRIs) are the first-line medication. The U.S. Food and Drug Administration (FDA) has approved four SSRIs for the treatment of PMDD: Fluoxetine (available as generic or as Prozac or Sarafem), sertraline (Zoloft), paroxetine (Paxil), and escitalopram oxalate (Lexapro). Unlike treatments for depressive disorders, SSRIs do not need to be taken daily but instead can be taken only in the luteal phase or during PMDD symptoms. This is because those who respond to SSRIs usually experience symptoms relief within 1–2 days. Studies in rats suggest this rapid response to SSRIs is due to the elevation of the neuroactive progesterone metabolite allopregnanolone in the brain, rather than serotonin. Luteal phase dosing can be started 14 days before menses and subsequently discontinued after start of menstrual flow. People taking SSRIs to ease PMDD generally report >50% alleviation in symptoms, which was significant improvement compared to placebo.
Although less studied, SNRIs have also shown benefit in PMDD. In a randomized, controlled clinical trial of women with PMDD, 60% of the people taking venlafaxine improved versus 35% on placebo. Improvement was noticed during the first treatment cycle with 80% symptom reduction.
Another FDA approved treatment for PMDD is the oral contraceptive with ethinylestradiol and drospirenone, a novel progestin. It has been shown that hormonal birth control containing drospirenone and low levels of estrogen helps relieve severe PMDD symptoms, for at least the first three months it is used. The idea behind using oral contraceptives is to suppress ovulation by controlling sex hormone fluctuations during the luteal phase.
Cognitive behavioral therapy (CBT) has been shown to be effective in PMS and is suggested as a successful adjunct to SSRI treatment. CBT is an evidence-based treatment approach for treating depression and focuses on the link between mood, thoughts, and actions to help patients address current issues and symptoms. When CBT was compared to SSRI alone or in combination with SSRI, groups receiving CBT had significant improvement of PMS symptoms. Through the practice of CBT, patients are better able to recognize and modify recurrent issues as well as thought and behavior patterns that interfere with functioning well or that make depressive symptoms worse.[medical citation needed]
When drug-based treatments are ineffective or produce significant side effects, then removing the ovaries through oophorectomy can produce an immediate and permanent cure. Typically, the uterus is removed during the same surgery, and the woman is prescribed a low-dose estrogen patch to reduce the symptoms produced by surgically induced menopause.
There have been some nutritional supplements that have been shown to help alleviate the symptoms of PMDD. In 1998, a placebo-controlled, randomized trial of 720 people with PMDD found that calcium carbonate demonstrated up to a 50% reduction in symptoms, compared with a 30% reduction in the control group. Herbal treatments that have shown promise in PMDD include chasteberry (Vitex agnus castus), St. John's wort (Hypericum perforatum), and ginkgo (Ginkgo biloba). Studies have been conducted on the efficacy of chasteberry and gingko, but as of this writing, no randomized controlled trial has been conducted on the efficacy of St. John's wort in alleviating PMDD symptoms.
20-30% of women who menstruate experience symptoms severe enough to meet PMS criteria and 3-8% of women who are of reproductive age meet the PMDD criteria.
Bipolar depression, anxiety disorders, and other Axis I disorders are more common in women with PMDD than in the general population. In women with PMDD, there is a 50-78% lifetime incidence of various psychiatric disorders such as generalized anxiety disorder, seasonal affective disorder and major depressive disorder.
The symptoms which coincide with mood disorders, such as major depressive disorder or bipolar disorder, may worsen during the premenstrual period and thus may mimic PMDD. This phenomenon is known as premenstrual exacerbation (PME) and refers to the worsening of mood disorder symptoms during the premenstrual phase. An estimated 40% of women who seek treatment for PMDD are found to not have PMDD, but rather a PME of an underlying mood disorder.[medical citation needed]
Medical personnel can avoid misdiagnosis by having women seeking treatment for PMDD use a daily charting method to record their symptoms. Daily charting helps distinguish when mood disturbances are experienced and allows PMDD to be distinguished from other mood disorders. With PMDD, mood symptoms are present only during the luteal phase, or last two weeks, of the menstrual cycle. While PMDD mood symptoms are of a cyclical nature, other mood disorders are variable or constant over time. Although the medical community lacks a consensus on the most efficient instrument by which to confirm a PMDD diagnosis, several well-validated scales for recording premenstrual symptoms include the Calendar of Premenstrual Experiences (COPE), Daily Record of Severity of Problems (DRSP), and Prospective Record of the Severity of Menstruation (PRISM).[medical citation needed]
PMDD mood symptoms are only present in women who are menstruating. Thus, symptoms do not occur during pregnancy and after menopause. Other mood disorders typically persist across all reproductive life events and are independent of a person's menstrual cycle or lack thereof.
In addition to Axis I disorders, several other medical illnesses such as chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome and migraine disorder may present symptoms similar or identical to those of PMDD.
Relationship to pregnancy
Women with PMDD usually see their symptoms disappear while they are pregnant. However, they have a high risk of experiencing postpartum depression. The first choice of treatment for postpartum depression in women with PMDD is a transdermal estrogen patch, sometimes supplemented with a testosterone patch and a low dose of progesterone.
The diagnostic category was discussed in the DSM-IIIR, published in 1987, in which the proposed condition was named "Late Luteal Phase Dysphoric Disorder" and included in an appendix as a proposed diagnostic category needing further study. Preparations for the DSM-IV led to debate about whether to keep the category at all, keep it in the appendix, or remove it; the reviewers determined that the condition was still too poorly studied and defined, so it was kept in the appendix but elaborated with diagnostic criteria to aid further study.
As preparations were underway in 1998 for the DSM-IV-TR, the conversation changed, as Eli Lilly and Company had paid for a large clinical trial of fluoxetine as a potential treatment for the condition that had been conducted by Canadian academics and published in the New England Journal of Medicine in 1995, and other studies had been conducted as well that all found that about 60% of people with PMDD in the trials improved with the drug; representatives from Lilly and the FDA participated in the discussion.
Various strong stances were taken in the discussion. For example, Sally Severino, a psychiatrist, argued that because PMDD symptoms were more prevalent in the US, it was a culture-bound syndrome and not a biological condition, and also said it was "an unnecessary pathologizing of cyclical changes in women." Jean Endicott, another psychiatrist and chair of the committee, has argued that it is a valid condition from which people suffer and should be diagnosed and treated, and has said: "If men had PMDD, it would have been studied a long time ago." In the end the committee kept PMDD in the appendix.
The decision has been criticized as being driven by Lilly's financial interests, and possibly by financial interests of members of the committee who had received funding from Lilly. Paula Caplan, a psychologist who had served on the committee for the DSM-IV, noted at the time of the DSM-IV-TR decision that there was some evidence that calcium supplements could treat PMDD but the committee hardly looked at them; she also had claimed that the diagnostic category is harmful to people with PMDD, leading them to believe they are mentally ill, and potentially leading others to mistrust them in situations as important as job promotions or child custody cases. She has called PMDD "an invented disorder." Nada Stotland has expressed concern that people with PMDD may actually have a more serious condition like major depressive disorder or may be in difficult circumstances, like suffering domestic abuse, may have their true issues remain undiagnosed and managed, if their gynecologist diagnoses them with PMDD and gives them drugs to treat that condition.
The validity of PMDD was once more debated when it came to time to create the DSM-5 in 2008. In the end it was moved out of the appendix and into the main text as a formal category; a review in the Journal of Clinical Psychiatry published in 2014 examined the arguments against inclusion, which it summarized as: "(1) the PMDD label will harm women economically, politically, legally, and domestically; (2) there is no equivalent hormonally based medical label for males; (3) the research on PMDD is faulty; (4) PMDD is a culture-bound condition; (5) PMDD is due to situational, rather than biological, factors; and (6) PMDD was fabricated by pharmaceutical companies for financial gain" and addressed each and found no evidence of harm, that no hormonally-driven disorder has been identified in men despite research seeking it; that the research base has matured; that PMDD has been identified worldwide; that a small minority of people do suffer from the condition; and that while there has been financial conflict of interest it has not made the research unusable. It concluded by noting that women have historically been under-treated and told that problems are "all in their heads", and that the formal diagnostic criteria would spur more funding, research, diagnosis and treatment for people who have PMDD.
- Rapkin, Andrea J; Lewis, Erin I (2013). "Treatment of Premenstrual Dysphoric Disorder". Women's Health. 9 (6): 537–56. doi:10.2217/whe.13.62. PMID 24161307.
- Steiner, M; Pearlstein, T; Cohen, LS (2006). "Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs". J Womens Health (Larchmt). 15 (1): 57–69. doi:10.1089/jwh.2006.15.57. PMID 16417420.
- Biggs WS, Demuth RH (October 2011). "Premenstrual syndrome and premenstrual dysphoric disorder". Am Fam Physician. 84 (8): 918–24. PMID 22010771.
- Hantsoo, Liisa; Epperson, C. Neill (2015). "Premenstrual Dysphoric Disorder: Epidemiology and Treatment". Current Psychiatry Reports. 17 (11): 87. doi:10.1007/s11920-015-0628-3. PMC . PMID 26377947.
- Epperson, C. Neill; Hantsoo, Liisa (2014). "Menstruation and Premenstrual Dysphoric Disorder: Its Impact on Mood". Women's Reproductive Mental Health Across the Lifespan. pp. 49–72. doi:10.1007/978-3-319-05116-1_3. ISBN 978-3-319-05115-4.
- Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychiatric Association. Code: 625.4 (N94.3)
- ACOG Committee on Practice Bulletins--Gynecology. (2000). "ACOG Practice Bulletin: No 15: Premenstrual syndrome". Obstetrics and gynecology. 95 (4): suppl 1–9. PMID 24829972.
- "Premenstrual Syndrome, Management (Green-top Guideline No. 48)". Royal College of Obstetricians & Gynaecologists. Retrieved 2015-11-05.
- o'Brien, Patrick Michael Shaughn; Bäckström, Torbjorn; Brown, Candace; Dennerstein, Lorraine; Endicott, Jean; Epperson, C. Neill; Eriksson, Elias; Freeman, Ellen; Halbreich, Uriel; Ismail, Khaled M. K.; Panay, Nicholas; Pearlstein, Teri; Rapkin, Andrea; Reid, Robert; Schmidt, Peter; Steiner, Meir; Studd, John; Yonkers, Kimberley (2011). "Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: The ISPMD Montreal consensus". Archives of Women's Mental Health. 14 (1): 13–21. doi:10.1007/s00737-010-0201-3. PMC . PMID 21225438.
- ICD-11: GA34.41 Premenstrual dysphoric disorder
- Worcester, Nancy; Whatley, eds, Mariamne H. (2004). Women's health: Readings on social, economic, and political issues. Sage Publications.
- Moynihan, R. (2004). "Controversial disease dropped from Prozac product information". BMJ. 328 (7436): 365. doi:10.1136/bmj.328.7436.365. PMC . PMID 14962861.
- European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (2003-06-13). "Summary Information...for Prozac and associated names" (PDF).
- Sertraline (Zoloft), fluoxetine (Lovan, Prozac) for premenstrual dysphoric disorder (PMDD) National Prescribing Service Limited. (Australia)
- Ward, Susan (2016). Maternal-Child Nursing Care. Philadelphia, PA, USA: F.A. Davis Company. ISBN 9780803636651.[page needed]
- Rapkin, Andrea J; Winer, Sharon A (2008). "The pharmacologic management of premenstrual dysphoric disorder". Expert Opinion on Pharmacotherapy. 9 (3): 429–45. doi:10.1517/146565126.96.36.1999. PMID 18220493.
- Fry, J P; Li, K Y; Devall, A J; Cockcroft, S; Honour, J W; Lovick, T A (2014). "Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase". British Journal of Pharmacology. 171 (24): 5870–80. doi:10.1111/bph.12891. PMC . PMID 25161074.
- Devall, Adam J.; Santos, Julia M.; Fry, Jonathan P.; Honour, John W.; Brandão, Marcus L.; Lovick, Thelma A. (2015). "Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats". European Neuropsychopharmacology. 25 (1): 113–23. doi:10.1016/j.euroneuro.2014.11.017. PMID 25498416.
- Freeman, E. W.; Rickels, K; Yonkers, K. A.; Kunz, N. R.; McPherson, M; Upton, G. V. (2001). "Venlafaxine in the treatment of premenstrual dysphoric disorder". Obstetrics and gynecology. 98 (5 Pt 1): 737–44. PMID 11704162.
- Lopez, LM.; Kaptein, AA.; Helmerhorst, FM. (2012). "Oral contraceptives containing drospirenone for premenstrual syndrome". Cochrane Database Syst Rev. 2 (2): CD006586. doi:10.1002/14651858.CD006586.pub4. PMID 22336820.
- Yonkers, Kimberly Ann; Simoni, Michael K. (January 2018). "Premenstrual disorders". American Journal of Obstetrics and Gynecology. 218 (1): 68–74. doi:10.1016/j.ajog.2017.05.045. ISSN 1097-6868. PMID 28571724.
- Reid, Robert L. (June 2012). "When should surgical treatment be considered for premenstrual dysphoric disorder?". Menopause International. 18 (2): 77–81. doi:10.1258/mi.2012.012009. ISSN 1754-0461. PMID 22611227.
- Berga, MD, Sarah L.; Spencer, MD, MS, Jessica B.; Dominguez, MD, Celia E. "PMDD Spotlight: Diagnosis and Treatment". Medscape.
- Thys-Jacobs, S.; Starkey, P.; Bernstein, D.; Tian, J. (1998-08-01). "Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group". American Journal of Obstetrics and Gynecology. 179 (2): 444–452. doi:10.1016/s0002-9378(98)70377-1. ISSN 0002-9378. PMID 9731851.
- Kim DR, Gyulai L, Freeman EW, Morrison MF, Baldassano C, Dubé B (February 2004). "Premenstrual dysphoric disorder and psychiatric co-morbidity". Arch Womens Ment Health. 7 (1): 37–47. doi:10.1007/s00737-003-0027-3. PMID 14963731.
- Studd, John; Nappi, Rossella E. (March 2012). "Reproductive depression". Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology. 28 Suppl 1: 42–45. doi:10.3109/09513590.2012.651932. ISSN 1473-0766. PMID 22394303.
- Spartos, Carla (December 5, 2000). "Sarafem Nation". Village Voice.
- Steiner, Meir; Steinberg, Susanne; Stewart, Donna; Carter, Diana; Berger, Charlene; Reid, Robert; Grover, Douglas; Streiner, David (1995). "Fluoxetine in the Treatment of Premenstrual Dysphoria". New England Journal of Medicine. 332 (23): 1529–34. doi:10.1056/NEJM199506083322301. PMID 7739706.
- Caplan, Paula (March 3, 2004). "The Debate About PMDD and Sarafem". Women & Therapy. 27 (3–4): 55–67. doi:10.1300/J015v27n03_05.
- Chen, Ingfei (December 18, 2008). "A Clash of Science and Politics Over PMS". New York Times. Archived from the original on January 23, 2011.
- Hartlage SA; et al. (Jan 2014). "Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5". J Clin Psychiatry. 75 (1): 70–6. doi:10.4088/JCP.13cs08368. PMID 24345853.
- Premenstrual dysphoric disorder at Curlie (based on DMOZ)
- Bhatia, S. C.; Bhatia, S. K. (2002). "Diagnosis and treatment of premenstrual dysphoric disorder". American Family Physician. 66 (7): 1239–48. PMID 12387436.